Martina Imbimbo
@MImbimbo1
Followers
139
Following
126
Statuses
63
Amazing opportunity @caliraf My time at the Christie has been so important in my development, as a clinician, researcher and person. Supporting mentors and high quality complete training.
We have a position available from Jan/Feb 2025. Fantastic opportunity to join the Lung Team @TheChristieNHS as Clinical Research Fellow (I will be Supervisor/Mentor). Post is full time for 1 year but renewable for another year
1
0
4
0
1
0
@fedenichetti @CellRepMed In many cases in combos effect of drugs is addictive more than sinergic (and maybe having 2 different MoA is very good?). Very interesting
0
0
1
RT @Ritalepp: Don’t miss the V edition of the #CocktailWithScience #LungCancer meeting in Milan🫁 👉🏻 Hosted by @GL…
0
6
0
RT @darioT_: I'm full of joy for having been interviewed by my friend and greatest scientist @elbairikhalid19 for the @ASCOPost ! #Global…
0
10
0
0
3
0
Such a delicate and important matter. Much to do and more to come! @Florez_Lab @fedrophd
🚨 NEW PUBLICATION ALERT! 🚨 Check out our latest publication in Elsevier's Journal of Thoracic Oncology: "From Approximation to Precision: Fertility and Pregnancy Questions in Young Patients with Lung Cancer." Link to read #LungCancerResearch
0
3
6
So cool! Cochrane lung cancer group !
Best post award for waning effect of adjuvant EGFR TKIs in resected NSCLC. Cochrane Metanalysis Lung Cancer Group. @CochraneLibrary @cochranecollab @MOcchipintiMD @MImbimbo1 @vittoriosimeon @giusvisc
#ELCC24
0
0
4
@PrelajArsela @polimi @marinagarassino @protoss1986 @jnkath @saramoccia @AI_ON_Lab @IstTumori Brava Arsi!!!! ☀️☀️☀️
0
0
0
AI will be more and more a tool for today's and tomorrow's oncologists. Don't miss this opportunity to showcase your work and connect with great faculty! #AIisthenewstethoscope(cit.)
Abstracts wanted! Showcase your work in AI for oncology and research by presenting an abstract for the 2nd edition of the AI for Oncology conference, held at @IstTumori on 10th May 2024- Register to the event: #ClinicalAI #AI4Onc24
0
1
4
Just out ph2 MEDIOLA trial Toward a chemo free regimen for women affected by ovarian cancer? 👇👇 - Olaparib + durva ➡️ notable activity in women with gBRCAm PSROC - Olaparib + durva + beva ➡️ encouraging activity in women with non-gBRCAm PSROC
0
0
3
Artificial (and w-human) intelligence at service of immunooncology @PrelajArsela
#IO23 driving innovation @RobertoFerrara_ @IASLC
0
4
18
Terrific congress, so honored to be in the faculty and share the session with 2 giants. Thanks to organizers for the comprehensive program, outstanding faculty and focus on translation research #IO23 @IASLC @RobertoFerrara_
My favorite TILs people explaining limitations and andvances of adoptive cell therapy in NSCLC. @BenCreelan, @MImbimbo1
@IASLC #IO23
0
2
10
So proud to see the amazing results of this Italian collaborative effort (Tyme network) at ESMO 23. A big step ahead for patients affected by this rare cancer
Results from RELEVENT trial confirm the role of antiangionetic in TC. The best first plus chemo: ORR 80%, DCR 100%, PFS 18mo and OS 43mo. Good safety profile. 💥💥💥 @IstTumori and TYME network #ESMO23
0
0
4
RT @MOcchipintiMD: Results from RELEVENT trial confirm the role of antiangionetic in TC. The best first plus chemo: ORR 80%, DCR 100%, PFS…
0
10
0
Super !!! @PrelajArsela knowledge, innovation and a big <3
Huge news as we celebrated the inauguration of Italy's first lab specifically dedicated to unleashing the potential of #AI to #CancerResearch. We couldn't have done it without the collaboration between @IstTumori and @polimi -@marinagarassino @lab_pearson @Vanja_Miskovic_
0
0
4
Want to be update on the state-of-art for treatment for Lung Cancer, and much more? Join in person or online, terrific faculty! @GLoRussoMD_PhD Congress is in English!
0
3
13
RT @pulmonary_news: 💫 Between myth and reality! #NSCLC Dr. Martina Imbimbo's (@MImbimbo1) team at @CHUVLausanne #review the current state…
0
2
0
🚨Cellular therapies and lung cancer. Where are we? What's new? Hope or hype? @DralexGva Read our review to find out 👇👇👇👇
0
1
12